The expression of differentiation-associated surface antigens by the clonogenic leukemic cells from 20 patients with acute myeloblastic leukemia (AML) was studied with a panel of seven cytotoxic monoclonal antibodies (anti-Ia, -MY9, -PM-81, -AML-2-23, -Mol, -Mo2, and -MY3). The surface antigen phenotypes of the clonogenic cells were compared with the phenotypes of the whole leukemic cell population, and with the phenotypes of normal hematopoietic progenitor cells. In each case the clonogenic leukemic cells were found within a distinct subpopulation that was less "differentiated" than the total cell population. Clonogenic leukemic cells from different patients could be divided into three phenotype groups. In the first group (7 of 20 cases), the clonogenic cells expressed surface antigens characteristic of the normal multipotent colonyforming cell (Ia, MY9). These cases tended to have "undifferentiated" (FAB Ml) morphology, and the total cell population generally lacked expression of "late" monocyte antigens such as MY3 and Mo2. A second group (seven cases) of clonogenic cells expressed surface antigens characteristic of an "early" (day 14) colony-forming unit granulocyte-monocyte (CFU-GM), and a third group (six cases) was characteristic of a "late" (day 7) CFU-GM. The cases in these latter two groups tended to have myelomonocytic (FAB M4) morphology and to express monocyte surface antigens. These results suggest that the clonogenic cells are a distinct subpopulation in all cases of AML, and may be derived from normal hematopoietic progenitor cells at multiple points in the differentiation pathway. The results further support the possibility that selected monoclonal antibodies have the potential to purge leukemic clonogenic cells from bone marrow in some AML patients without eliminating critical normal progenitor cells.
Introduction
Acute myeloblastic leukemia (AML)' is a clonal malignant disorder of myeloid progenitor cells that results in the progres-sive accumulation of leukemic cells that fail to differentiate normally (1) . A small subset of leukemic cells from many patients with AML has the ability to form a colony in vitro in semisolid medium (2, 3) . These clonogenic cells, leukemic colony-forming cells (L-CFC), have several properties that are not shared by the majority of leukemic cells: a high fraction of L-CFC is in S-phase (4), the cells have the ability to divide five or more times in vitro, and at least a subset of L-CFC has self-renewal capability (5) . L-CFC share these properties with normal myeloid progenitor cells, and it has been suggested that the L-CFC act in vivo as progenitor cells to maintain the rest of the leukemic cell population (4, 6) . However, despite having properties of a progenitor cell, the relationships between L-CFC and the total leukemic population have not been defined.
We have previously demonstrated that differentiation-associated myeloid surface antigens detected by monoclonal antibodies could be used to identify L-CFC as a distinct subpopulation of cells in some patients with acute myelomonocytic leukemia (AMML) (7) . It was shown that L-CFC expressed antigens characteristic of very immature cells (Ia, MY7) but lacked MY4, an antigen characteristic of later monocytic cells, despite the fact that a majority ofthe leukemic cells in AMML patients express MY4. These preliminary observations thus suggested that the highly proliferative MY4 negative L-CFC may indeed function as progenitor cells, giving rise to MY4 positive cells that have minimal proliferative potential, a situation analogous in some respects to normal myelopoiesis.
In this study, we have investigated the surface antigens of L-CFC in 20 patients with AML with the goals of (a) comparing L-CFC with the majority of the leukemic cells in each patient; (b) comparing L-CFC from different AML patients of different morphologic subtypes, and (c) comparing L-CFC with normal bone marrow colony-forming cells. The results demonstrate that L-CFC are a distinct subpopulation of leukemic cells in virtually all cases of AML and can be distinguished from more differentiated leukemic cells by their surface antigen phenotype. Three different "stages" of L-CFC were defined by the progressive acquisition of surface antigens in a sequence analogous to normal granulocyte-monocyte progenitor cell maturation. Finally, the degree of in vivo differentiation of leukemic cells in individual AML patients is at least partially dependent on the stage of L-CFC present in that patient.
Methods
Monoclonal antibodies. Production and characterization of murine monoclonal antibodies anti-MY3, anti-MY9, anti-AML-2-23, and anti-PM-8 1 have been previously described (8-1 1) . Anti (14) , and confirmed by surface marker analysis (2 1). (Table II) .
As shown in Table II express PM-8 1 (on 59% of cells). The most mature clonogenic cell, the day 7 CFU-GM, expresses Ia, MY9, and PM-8 1, and now also expresses AML-2-23 antigen. As shown in Table II , the acquisition of these differentiation-associated antigens during normal hematopoiesis may be "gradual," particularly in the cases of PM-81 and AML-2-23 antigens as summarized schematically in Fig. 1 (Table IV) . Within each group, the leukemic cell populations have acquired surface antigens that are not expressed on the L-CFC as noted above. For example, a majority of cells in the total cell population of cases in group I expressed PM-81, AML-2-23, and Mol in addition to la and MY9 antigens present onithe L-CFC. Group II patients tend to acquire AML-2-23, Mol, and Mo2 on the total cell population, while group III patients expressed Mol in 100% of the cases, Mo2. in 67%, and MY3 in 67%. The FAB subsets were disproportionately distributed among the L-CFC groups, with all of the Ml patients in group I, and 91% of the M4 patients in groups II and III. These results suggest that the surface antigens and thus the level of differentiation attained by the majority leukemic cell population (21) in many cases of AML are at least partially related to the stage of differentiation of the L-CFC. These results also make it possible to relate the L-CFC to a counterpart normal myeloid cell. The relationship between the phenotypes of L-CFC and normal myeloid progenitor cells is illustrated schematically in Fig. 3 . (Table III) . Interestingly, these antigens are acquired in normal granulocytemonocytic differentiation in the same sequence ( Fig. 1 and (26) reported that a marker translocation t (lq-; 1llq+) could be found in normal appearing CFU-GM from a child with AML, suggesting that an early stem might be involved in the pathogenesis of some cases of AML. The results presented here support the observation of Fialkow (1) that some cases of AML may originate in a multipotent progenitor cell, while others arise in a later cell already committed to the myeloid lineage. The possibility exists, however, that pluripotent stem cells are involved in the leukemic process in most cases of AML, but fail to proliferate in the assay system used here or are present in very small numbers. Several observations tend to support the concept that the L-CFC assayed in this study are representative of the major clonogenic cell that can be cultured. First, L-CFC with the phenotype of a multipotent cell were observed in a distinct subset of cases, demonstrating that such cells can be identified with this culture system. Second, the clonogenic cells in each case of AML tended to be a relatively uniform subset. Multiple levels of L-CFC in the same patient thus were generally not observed, even though L-CFC were strikingly different in different patients. Finally, the majority of leukemic colonies in individual cases tended to be of uniform size -(generally 20-40 cells) and to follow similar kinetics in culture, suggesting that the L-CFC are a reasonably homogeneous population with respect to proliferative potential, unlike normal bone marrow progenitor cells. However, it is not possible to be certain that any culture system will promote gtowth of the earliest possible leukemic progenitor cell, or that the in vitro clonogenic cells are representative of in vivo stem cells. Similar studies need to be done with the other L-CFC culture systems (3, 27, 28) . It may be possible to determn ine if the different assay systems detect the same L-CFC cell by using the surface antigen phenotype methods described here. Data from other laboratories suggest that agar and methyl cellulose L-CFC culture systems may be similar (15) . In our own pilot studies comparing agar and methylcellulose cultures, no reproducible differences in colony number or size were observed. Agar was selected because of the ease with which whole cultures could be stained cytochemically for myeloid specific esterase activities. We chose to avoid conditions that would support the growth of T cell colonies (phytohemagglutinin or phytohemagglutinin-stimulated leukocyte conditioned medium) (28). Every effort was also made here to avoid "contamination" of leukemic cells with residual normal CFU-GM by testing only patients with near total replacement of marrow by leukemic cells, and by testing peripheral blood when possible (where the number of possible residual normal myeloid progenitor cells is several orders of magnitude lower than the number of L-CFC).
The differentiation stage of the L-CFC did not correlate with age in this study. Pediatric cases were equally distributed amdng the groups of both multipotent and more differentiated L-CFC, and the two oldest patients (patients 19 and 20) had L-CFC in the most differentiated group (III). The AML patients studied here, however, were de novo cases and did not include patients with a prior history of a myelodysplastic syndrome or a myeloproliferative disease. In these stem cell disorders, the L-CPC tnight be anticipated to be more uniformly related to a multipotent cell. However, it is also possible that the final leukemic transforming event in these patients also takes place in a later progenitor cell. It There is ample evidence that AML cells and AML cell lines can be induced to differentiate in vitro (8, (29) (30) (31) (32) . If the L-CFC assayed in vitro do indeed function as leukemic stem cells in vivo, then our results suggest that partial and often abnormal degrees of differentiation are an on-going process in vivo. It is interesting, however, that different stages of L-CFC appear to have different abilities to differentiate, thus resulting in different morphological and immunological phenotypes. The most immature L-CFC (group I) tended to be associated with FAB classification M l, while the more differentiated L-CFC (groups II and III) tended to be associated with M4 and M5 (Table IV) . The expression of surface antigens on the total cell population was also related to the degree of differentiation of the L-CFC. Thus, although Ia, MY9, and PM-81 antigens were expressed on the leukemic cells of all patients, the percentage of cases expressing AML-2-23, Mo 1, Mo2, and MY3, and the percentage of cells in each individual case expressing these antigens, tended to increase from group I to group II to group III. The analogies between leukemic and normal differentiation are summarized in Fig. 3 .
The results presented here have several implications for the therapy of AML. The ability to immunologically purge leukemic progenitor cells from a remission bone marrow could allow autologous bone marrow transplantation despite the lack of leukemia-specific markers. This approach has been used successfully in the treatment of acute lymphoblastic leukemia (anti-CALLA) (33) 
